Publications by authors named "O Rubio Cabezas"
Human erythropoietin is mainly recognized for its hematopoietic function; however, by binding to its receptor (EpoR), it can activate different signaling pathways as STAT, PI3K, MAPK and RAS to increase cellular differentiation or provide neuroprotective effects, among others. A recombinant human erythropoietin variant with low glycosylation and without hematopoietic effect (EpoL) was purified from skimmed goat milk. Recombinant human erythropoietin (Epo) was obtained from CHO cell line and used as control to compare EpoL effects.
View Article and Find Full Text PDFHyperinsulinemic hypoglycemia (HI) and congenital polycystic kidney disease (PKD) are rare, genetically heterogeneous disorders. The co-occurrence of these disorders (HIPKD) in 17 children from 11 unrelated families suggested an unrecognized genetic disorder. Whole-genome linkage analysis in five informative families identified a single significant locus on chromosome 16p13.
View Article and Find Full Text PDFArticle Synopsis
- Recombinant erythropoietin (EPO) is used for treating anemia and chronic renal failure, and newer long-acting variants have been developed for less frequent dosing through modifications like glycosylation.
- High levels of EPO were successfully produced in goat's milk using an adenoviral vector, showing that the molecular weight of EPO-Fc affects its hematopoietic activity.
- The study concludes that the types of sugars (sialylated N-glycans) attached to EPO-Fc significantly influence its biological activity in the body, more than just its molecular weight.